SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

AIM ImmunoTech Inc. – ‘8-K’ for 5/5/21

On:  Thursday, 5/6/21, at 1:45pm ET   ·   For:  5/5/21   ·   Accession #:  1493152-21-10587   ·   File #:  1-27072

Previous ‘8-K’:  ‘8-K’ on / for 5/3/21   ·   Next:  ‘8-K’ on / for 5/18/21   ·   Latest:  ‘8-K’ on 2/20/24 for 2/16/24   ·   3 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/06/21  AIM ImmunoTech Inc.               8-K:8       5/05/21    1:29K                                    M2 Compliance LLC/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     15K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

May 5, 2021

 

AIM IMMUNOTECH INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001 - 27072   52-0845822
(state or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

2117 SW Highway 484, Ocala FL   34473
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (352) 448-7797

 

AIM ImmunoTech Inc.

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.001 per share   AIM   NYSE American

 

 

 

 C: 
 
 

 

Item 8.01 Other Events.

 

On May 5, 2021, AIM ImmunoTech Inc. (the “Company”) filed one U.S. Provisional Patent Application for the Company’s drug Ampligen as a potential therapeutic to possibly slow, halt, or reverse the progression of Alzheimer’s disease.

 

Cautionary Statement

 

No assurance can be given that this patent application or subsequent patent applications claiming priority to this application ultimately will be granted. In addition, whether or not Ampligen will be accepted as an approved therapeutic to slow, halt or reverse the progression of Alzheimer’s disease, will require significant testing, clinical trials, and regulatory approval. The Company cannot assure that any such trials will be successful, yield favorable data or not require additional funding. Clinical trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials.

 

 C: 
 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AIM IMMUNOTECH INC.
     
May 6, 2021 By: /s/ Thomas K. Equels
    Thomas K. Equels, CEO

 

 C: 
 

 


Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on:5/6/21None on these Dates
For Period end:5/5/21
 List all Filings 


3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/19/23  AIM ImmunoTech Inc.               424B5                  1:431K                                   M2 Compliance LLC/FA
 7/01/22  AIM ImmunoTech Inc.               S-8         7/01/22    4:143K                                   M2 Compliance LLC/FA
 7/01/21  AIM ImmunoTech Inc.               S-8         7/01/21    4:140K                                   M2 Compliance LLC/FA
Top
Filing Submission 0001493152-21-010587   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 5:32:19.1am ET